All Trials
-
2nd SYMPHONY
- Cardiology
- PHASE III
- 6,671 participants
- 15 sites in New Zealand
- 625 sites globally
Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post-Acute Coronary Syndromes. Randomised trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes in 6,671 patients.
More about the 2nd SYMPHONY study -
ACUITY
- Cardiology
- PHASE III
- 13,800 participants
- 4 sites in New Zealand
- 600 sites globally
A randomised comparison of Angiomax® (bilvalirudin) versus heparin (enoxaparin or unfractionated heparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation. Randomisation is also designed to compare the timings of initiation of GPIIb/IIIa inhibitors in this population. This phase III global study is expected to be conducted at 600 sites in North America, Europe and Australasia with a total 13,800 patients followed up for 1 year.
More about the ACUITY study -
APEX AMI
- Cardiology
- PHASE III
- 8,500 participants
- 5 sites in New Zealand
A Multicentre, Randomised, Double-Blind, Parallel-group, Placebo-controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
More about the APEX AMI study -
ATLAS
- Cardiology
- PHASE II
- 3,491 participants
- 10 sites in New Zealand
The ATLAS ACS TIMI 46 Trial (Anti-Xa Therapy to Lower cardiovascular events in addition to Aspirin with or without thienopyridine therapy in Subjects with Acute Coronary Syndrome)
A Randomised, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with Aspirin and Thienopyridine in Subjects with Acute Coronary Syndromes
This is a phase II randomised, multicentre, double-blind, placebo-controlled study involving the use of an investigational drug Rivaroxaban. The purpose of this study is to evaluate the safety and efficacy of rivaroxaban and to determine what dose of rivaroxaban works the best for reducing blood clotting in the heart artery in participants with recent heart attack or unstable angina who are receiving background low dose-aspirin therapy.
More about the ATLAS study -
CARISA
- Cardiology
- PHASE III
- 600 participants
- 2 sites in New Zealand
Combination Assessment of Ranolazine In Stable Angina. An open-label, long-term, safety study of Ranolazine SR for chronic stable angina pectoris at doses of 500mg, 750mg and 1000mg twice a day administered in combination with background anti-anginal therapy.
More about the CARISA study -
CARISA - Ranolanzine CVT 3033
- Cardiology
- PHASE III
- 648 participants
- 6 sites in New Zealand
Combination Assessment of Ranolazine In Stable Angina. A double-blind, randomized, stratified, placebo-controlled, parallel study of Ranolazine SR at doses of 750mg twice a day and 1000mg twice a day in combination with other anti-anginal medications in 648 patients with Chronic stable angina pectoris.
More about the CARISA study -
CHAMPION PCI
- Cardiology
- PHASE III
- 8,877 participants
- 6 sites in New Zealand
- 268 sites in 14 countries
CHAMPION – Cangrelor for High Risk Advanced Modern Percutaneous InterventiON
This is a phase III clinical trial comparing cangrelor (study medication) to clopidogrel (standard treatment) in participants who require percutaneous coronary intervention (with or without stent). The purpose of this trial is to compare the effects of cangrelor with the standard treatment, clopidogrel.
More about the CHAMPION PCI study -
CHAMPION PLATFORM
- Cardiology
- PHASE III
- 5,362 participants
- 4 sites in New Zealand
- 218 sites in 18 countries
CHAMPION Platform – Cangrelor versus standard therapy to achieve optimal management of platelet inhibition
This is a phase III clinical trial comparing treatment with cangrelor (in combination with usual care) to usual care, in subjects who require percutaneous coronary intervention. The primary objective is to demonstrate that the efficacy of cangrelor (combined with usual care is superior to that of usual care, in subjects requiring PCI as measured by a composite of all-cause mortality, MI and IDR.
More about the CHAMPION PLATFORM study -
COBALT
- Cardiology
- PHASE III
- 7,169 participants
The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. 398 hospitals participated with a total enrollment of 7,169 patients.
More about the COBALT study -
CURRENT / OASIS-7
- Cardiology
- PHASE III
- 18,000 participants
- 7 sites in New Zealand
- 600-800 sites globally
Randomised, multinational, double-blind study, comparing a high loading dose regimen of clopidogrel versus standard dose in patients with unstable angina or non-ST segment elevation myocardial infarction managed with an early invasive strategy
This is a phase III, multinational, multicentre, randomised, factorial design, parallel-group study comparing 2 regimens of clopidogrel (high versus standard dose) in a double-blind fashion and 2 regimens of aspirin (high versus low dose) in an open-label fashion in participants with symptoms of acute coronary disease who undergo a percutaneous coronary intervention as early as possible within 24 hours.
For further information, please visit http://clinicaltrials.gov/ct2/show/NCT00335452?term=NCT00335452&rank=1
More about the CURRENT / OASIS-7 study -
EARLY ACS
- Cardiology
- PHASE IV
- 10,500 participants
- 4 sites in New Zealand
- 500 sites globally
Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomised, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome
This was a multi-national, randomised, placebo-controlled, double-blind, parallel-group trial evaluating the clinical benefits of early front-loaded Eptifibadite in treatment of participants with Non-ST-segment Elevation Acute Coronary Syndrome” NSTE ACS (significant heart pain or heart attack) who were planned to undergo an invasive strategy no sooner than the next calendar day following randomisation. In New Zealand, this study was conducted as Phase IV study as eptifibatide is a registered drug.
More about the EARLY ACS study -
EPHESUS Trial
- Cardiology
- PHASE III
- 6,200 participants
- 5 sites in New Zealand
Eplerenone In Heart Failure Post Acute Myocardial Infarction. Double-blind, randomised, placebo-controlled trial evaluating the safety and efficacy of eplerenone in patients with heart failure following acute myocardial infarction.
More about the EPHESUS study -
EXPEDITION
- Cardiology
- PHASE III
- 2 sites in New Zealand
Na+/H+ Excahnge Inhibition to Prevent Coronary Events in Acute Cardiac Conditions. A double-blind, placebo controlled, multinational trial to investigate the effect of IV treatment with the Na+/H+ exchange inhibitor cariporide (HOE642) on all-cause mortality and non-fatal myocardial infarction in patients at risk of myocardial necrosis during and after coronary artery bypass graft (CABG) surgery.
More about the EXPEDITION study -
ExTRACT-TIMI 25
- Cardiology
- PHASE III
- 21,000 participants
- 14 sites in New Zealand
Enoxiparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment. A randomised, double-blind, double-dummy, parallel group, multinational, clinical study to evaluate the efficacy and safety of enoxaparin versus unfractionated heparin in patients with acute ST-segment elevation myocardial infarction receiving fibrinolytic therapy.
More about the ExTRACT-TIMI 25 study -
GISSI 2
- Cardiology
- PHASE III
- 12,490 participants
Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI). GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction.
More about the GISSI 2 study -
GUSTO I
- Cardiology
- PHASE III
- 41,021 participants
- 14 sites in New Zealand
- 1,081 sites globally
The Global Use of Strategies to Open Occluded Coronary Arteries. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction in 15 countries and 1,081 hospitals, enrolling 41,021 patients.
More about the GUSTO I study -
GUSTO IIa
- Cardiology
- PHASE III
- 2,564 participants
- 18 sites in New Zealand
- 227 sites globally
The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. At 275 participating hospitals in 12 countries, with enrollment of 2,564 patients.
More about the GUSTO IIa study -
GUSTO IIb
- Cardiology
- PHASE III
- 12,142 patients
- 18 sites in New Zealand
- 373 sites globally
The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. 373 hospitals in 13 countries enrolled 12,142 patients.
More about the GUSTO IIb study -
GUSTO III
- Cardiology
- PHASE III
- 15,059 participants
- 20 sites in New Zealand
- 807 sites globally
The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. A total of 15,059 patients from 807 hospitals in 20 countries.
More about the GUSTO III study -
GUSTO IV
- Cardiology
- PHASE III
- 7,825 participants
- 4 sites in New Zealand
- 458 sites globally
The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO IV) Investigators. A trial evaluating the efficacy and safety of ReoProâ?¢, given as a bolus followed by a 24- or 48- hour infusion, for the treatment of Acute Coronary Syndrome without ST-segment elevation.
More about the GUSTO IV study -
HERO-2
- Cardiology
- PHASE III
- 17,091 participants
- 12 sites in New Zealand
- 11 sites in India
- 3 sites in Hong Kong
- 3 sites in Malaysia
- 3 sites in Philippines
- 1 site in Thailand
- 539 sites in 47 countries
Hirulog Early Reperfusion/Occlusion. An open prospectively randomised comparison of Hirulog versus Heparin in patients receiving Aspirin and thrombolysis (Streptokinase) for the treatment of acute myocardial infarction. 17,091 patients at 539 sites in 47 countries.
More about the HERO-2 study -
ISIS-2
- Cardiology
- PHASE III
- 17,187 participants
**ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction in 417 hospitals.
More about the ISIS-2 study -
ISIS-3
- Cardiology
- PHASE III
- 41,299 participants
ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction.
More about the ISIS-3 study -
ISIS-4
- Cardiology
- PHASE III
- 58,050 participants
ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients entering 1086 hospitals with suspected acute myocardial infarction.
More about the ISIS-4 study -
MIG
- Gestational Diabetes
- PHASE IV
- 750 participants
- 12 sites in New Zealand
Gestational Diabetes; treatment with metformin compared with insulin. Sample size is 750 subjects to be recruited from centres in Australia and New Zealand. The trial is expected to be completed in 2-3 years.
More about the MIG study -
New Zealand Heart Valve Study
- Cardiology
- PHASE II
- 400 participants
- 6 sites in New Zealand
To determine whether natriuretic peptides are a reliable and clinically useful non-invasive marker of severity, progression, and left ventricular remodelling in aortic valve disease. 3 year follow-up. Sample size 400 patients.
More about the HVS study -
PARAGON-A
- Cardiology
- PHASE III
- 2,282 participants
- 16 sites in New Zealand
- 273 sites globally
Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organisation Network. An international, randomised, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. 273 hospitals in 20 countries randomised 2,282 patients.
More about the PARAGON-A study -
PARAGON-B
- Cardiology
- PHASE III
- 5,225 participants
- 14 sites in New Zealand
- 389 sites globally
The PARAGON-B Investigators. Randomised, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. 5,225 patients enrolled at 389 centers in 29 countries.
More about the PARAGON-B study -
RESDIO AP
- Device
- PHASE
- 300 participants
- 4 sites in New Zealand
- 1 site in Australia
Randomised Controlled Trial Evaluating Safety of Device Implantation in Orally Anticoagulated Patients (RESDIO-AP trial).
A randomised, single-blinded, controlled trial comparing device implantation in patients with therapeutic levels of anticoagulation (INR 2.0-3.0) to those with an INR <1.5 at the time of the surgical procedure.
This is a randomised, single blinded, controlled trial comparing device implantation in participants with therapeutic levels of anticoagulation (INR 2.0-3.0) to those with an INR <1.5 at the time of the surgical procedure. The purpose of this study is to prospectively evaluate the safety and efficacy of device implantation in patients with therapeutic levels of anticoagulation (INR 2.0-3.0) in a multi-centre randomised controlled trial. The study is to be conducted at 5 centres located in NZ and Australia.
More about the RESDIO AP study -
SYMPHONY
- Cardiology
- PHASE III
- 9,233 participants
- 13 sites in New Zealand
- 670 sites globally
Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post-Acute Coronary Syndromes. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial of 9,233 patients.
More about the SYMPHONY study -
VALIANT
- Cardiology
- PHASE III
- 14,500 participants
- 12 sites in New Zealand
Valsartan In Acute myocardial infarction. Multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with valsartan, captopril and their combination in high-risk patients after myocardial infarction. Sample Size 14,500.
More about the VALIANT study -
ZEST
- Cardiology
- PHASE IIb
- 66 participants
- 8 sites in New Zealand
New Zealand Eplerenone Aortic Stenosis Trial. A randomised double-blinded placebo controlled trial to investigate the effects of long-term treatment with the aldosterone receptor antagonist eplerenone on the left ventricular mass and volume with magnetic resonance imaging in patients with asymptomatic moderate to severe aortic stenosis. Sample size: 66 patients. Timeframe: 36 months.
More about the ZEST study